Part 3/12:
Professor Chen from Singapore’s National University Hospital explains that Aducanumab is an antibody designed to eliminate amyloid deposits. In clinical trials involving nearly 1,800 participants globally, including 13 Singaporeans, the drug demonstrated significant results. Brain imaging scans, particularly PET scans, reveal reductions in amyloid buildup after treatment, showcasing its potential to alter disease progression.